SASKATOON, Saskatchewan, November 28, 2025 (GLOBE NEWSWIRE) — PHARMACORP RX INC. (“PharmaCorp” or “Corporation(TSXV: PCRX), a growing national platform for pharmacist-led community pharmacy owners, today announced its financial results for the three and nine months ended September 30, 2025.
The third quarter reflected continued operating momentum, growth in the financial performance of individual pharmacies driven by revenue growth, improved profitability, improved operating efficiency and consistent progress in executing the Corporation's national acquisition strategy. During the quarter, PharmaCorp completed the acquisition of 3 pharmacies: 2 in Western Canada and 1 in Eastern Canada, further expanding its reach and strengthening the platform's global ambitions.
Financial results for the third quarter of 2025
- Revenues are driven by continued growth in prescription drug volumes and store shelf sales.
- Same-store sales (a financial supplementary measure) increased 9.4% compared to the third quarter of 2024, reflecting continued organic growth in our pharmacy network.
- Prescription volumes continue to grow, with total prescriptions up 7.2% year over year compared to the third quarter of 2024, demonstrating sustained patient engagement and activity across the network.
- Operational infrastructure was successfully deployed to support national scalability, including systems integration, pharmacy connectivity and shared ownership.
- The net loss for the quarter reflects continued investments in corporate infrastructure, stock options granted to directors and officers on July 18, 2025, and one-time legal costs to obtain our credit facility from CIBC.
- Stable pharmacy-level return on investment and disciplined weighted average EBITDA across all acquisitions support PharmaCorp's long-term accretive growth model.
Management comment
“We are encouraged by the strong performance of our initial acquisitions and continued interest from independent pharmacy owners to explore succession options,” said Alan Simpson, executive chairman of PharmaCorp. “This quarter demonstrates steady progress in scaling the business through disciplined and methodical execution. We remain committed to maintaining a disciplined weighted average EBITDA across all transactions, which reinforces our goal of achieving incremental growth.”
Live update
During the quarter, the Corporation made key investments in the systems, people and integration processes needed to support scalable national growth. The reported net loss includes options granted to directors and officers on July 18, 2025 and one-time legal costs to obtain our credit facility with CIBC.
Subsequent events
On October 2, 2025, PharmaCorp announced the acquisition of 100% of two pharmacies located in Western Canada, one of which includes adjacent land and building. The aggregate purchase price for 100% of the shares was US$3,400,000 and was financed through a combination of cash and stock.
On October 2, 2025, PharmaCorp announced the acquisition of 100% of the pharmacy located in eastern Canada. The aggregate purchase price for 100% of the shares was $5,300,000 and was financed by cash and available funds under the Corporation's credit facility.
On November 12, 2025, PharmaCorp announced the closing of a previously announced public acquisition transaction led by Canaccord Genuity Corp. and Acumen Capital Finance Partners Limited, which includes Raymond James Ltd., iA Private Wealth Inc. and Bloom Burton Securities Inc. (“Underwriters“), pursuant to which the Underwriters purchased 54,855,000 units in the purchase transaction (“Units“) in the capital of the Corporation at a price of C$0.42 per unit, for which aggregate gross proceeds to PharmaCorp were approximately C$23.0 million, including the full exercise of the over-allotment option.
Additional information
For further information regarding PharmaCorp's financial results for the three and nine months ended September 30, 2025 and its financial position as of that date, see PharmaCorp's unaudited condensed consolidated interim financial statements and related management's discussion and analysis for the three and nine months ended September 30, 2025, filed on SEDAR+ at www.sedarplus.ca.
Additional financial measures
This press release also mentions “same store sales”, which is an additional financial measure. “Same-store sales” are defined as sales from PharmaCorp-owned and operated pharmacies as of the end of the current reporting period, plus historical sales information from pharmacy operating systems. It is used to provide investors with additional assessment of the Corporation's operating performance and thereby identify trends in its underlying business that may not otherwise be apparent when relying solely on IFRS financial measures. Management uses additional financial measures, such as same-store sales, to facilitate comparisons of operating performance from period to period. Management also believes that additional financial measures are important to investors because they provide investors with a better understanding of the level of growth of our business. The Corporation cautions readers that same-store sales used in this press release may not be comparable to similar measures used by other issuers.
About PharmaCorp Rx Inc.
PharmaCorp is a Canadian pharmacy acquisition and ownership platform that aims to empower pharmacists as equity partners and support the succession of retired pharmacy owners. Through a combination of capital, strategic support and operational expertise, PharmaCorp is building a national network of community pharmacies under the PharmaChoice Canada brand. PharmaCorp currently operates seven PharmaChoice Canada-branded pharmacies and will continue to acquire both PharmaChoice Canada-branded pharmacies and independent pharmacies across Canada, rebranding non-banner pharmacies under the PharmaChoice Canada platform in line with its strategic alliance with PharmaChoice Canada. PharmaCorp shares trade on the TSX Venture Exchange under the symbol PCRX.
PharmaCorp actively encourages discussions with pharmacy owners regarding succession or divestment issues. For more information about our program and purchasing process, visit www.PharmaCorpRx.ca or contact our team confidentially. We are committed to a smooth transition that protects your legacy and serves your community.
For more information contact:
Investor Relations
[email protected]
Tel: (306) 536-3771
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking information: This press release contains “forward-looking information” regarding the Corporation within the meaning of applicable Canadian securities laws. All statements other than statements of historical fact included herein constitute forward-looking information. In particular, this press release contains forward-looking information with respect to: the Corporation's continued progress in implementing the Corporation's national acquisition strategy; the Corporation's coast-to-coast platform and acquisition ambitions; long-term model of accretive growth of the Corporation; continued interest from independent pharmacy owners considering succession options; the Corporation's commitment to maintaining a disciplined weighted average EBITDA ratio across all operations, which reinforces the Corporation's goal of achieving incremental growth; and the Corporation's goal to continue to acquire pharmacies as they enter the market and to operate such pharmacies under the PharmaChoice Canada brand. This forward-looking information reflects current beliefs and is based on information currently available to management of the Corporation and on assumptions that the Corporation believes to be reasonable. These assumptions include, but are not limited to: continued interest from independent pharmacy owners considering succession options; the volume of acquisition opportunities available to the Corporation is equal to or greater than historical volumes; and the continued supply of pharmacies for purchase by the Corporation at prices satisfactory to the Corporation and the Corporation's ability to purchase such pharmacies. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Corporation to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to obtain board, third party or regulatory approvals; competition; changes in legislation, including regulation of pharmacies, affecting the Corporation; timing and availability of external financing on acceptable terms; findings from economic assessments and assessments; and shortages of skilled, skilled labor or loss of key individuals. A description of additional risk factors that could cause actual results to differ materially from forward-looking information can be found in the Corporation's disclosure documents on SEDAR+ at www.sedarplus.ca. Although the Corporation has attempted to identify important risks and factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as expected, estimated or intended. Readers are cautioned that the above list of factors is not exhaustive. Readers are also cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations on which they are based will occur. The forward-looking information contained in this press release is expressly qualified by this cautionary statement. The forward-looking information contained in this press release reflects the Corporation's expectations as of the date of this press release and, accordingly, are subject to change after such date. However, the Corporation expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.
